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Inhibitory efﬁciencyHerewe demonstrate that the presence of the L-domain in calpastatins induces biphasic interactionwith calpain.
Competition experiments revealed that the L-domain is involved in positioning the ﬁrst inhibitory unit in close
and correct proximity to the calpain active site cleft, both in the closed and in the open conformation. At high con-
centrations of calpastatin, the multiple EF-hand structures in domains IV and VI of calpain can bind calpastatin,
maintaining the active site accessible to substrate. Based on these observations, we hypothesize that two distinct
calpain–calpastatin complexes may occur in which calpain can be either fully inhibited (I) or fully active (II). In
complex II the accessible calpain active site can be occupied by an additional calpastatin molecule, now a
cleavable substrate. The consequent proteolysis promotes the accumulation of calpastatin free inhibitory units
which are able of improving the capacity of the cell to inhibit calpain. This process operates under conditions
of prolonged [Ca2+] alteration, as seen for instance in Familial Amyotrophic Lateral Sclerosis (FALS) in which
calpastatin levels are increased. Our ﬁndings show that the L-domain of calpastatin plays a crucial role in
determining the formation of complexes with calpain in which calpain can be either inhibited or still active.
Moreover, the presence of multiple inhibitory domains in native full-length calpastatin molecules provides a
reservoir of potential inhibitory units to be used to counteract aberrant calpain activity.39 010 35338162.© 2014 Elsevier B.V. All rights reserved.1. Introduction
Calpains are proteins that belong to a family of Ca2+-dependent
cysteine proteases and are ubiquitously distributed and localized in
the cytosol along with their endogenous inhibitor calpastatin [1–4].
These proteases have been widely studied as they regulate the function
of speciﬁc proteins by selective cleavage in response to calcium signal-
ing [5–9].
Abnormal activity of calpain has been associated with several path-
ological conditions characterized by alterations in Ca2+ homeostasis
[10–15]. Because efﬁcient [Ca2+]i control is crucial to the physiological
function of the calpain/calpastatin system, special efforts have been di-
rected at characterizing the mechanisms that control calpain activity
and the conditions that promote aberrant calpain function [16–20].
Occurrence of the transition to abnormal function in the presence
of persistent [Ca2+]i alteration, indicates that calpain proteolysis is
not sufﬁciently regulated by calpastatin inhibition. Furthermore,
co-localization in the same cellular compartment of calpain and ofa large excess of calpastatin, makes it difﬁcult to explain how calpain-
mediated proteolysis can normally occur, pointing to the existence
of mechanisms that allow calpain to escape from inhibition by
calpastatin.
It is known that, following [Ca2+]i increase, calpastatin diffuses in
the cytosol to control the amount of calpain that translocates to theplas-
ma membranes. Because calpastatin remains conﬁned in the cytosol,
the membrane-associated calpain can undergo activation. Therefore,
membranes are generally considered the preferential site of calpain
activity [1–4,21,22].
Another mechanism that controls the amount of inhibitor available
for interaction with calpain involves phosphorylation of calpastatin at
the L-domain [23–26]. This process affects the inhibitory efﬁciency
and selectivity of calpastatin, and can promote changes in its localiza-
tion [23,24,26,27] by modulating calpain activity under conditions of
elevated [Ca2+]i [23,27].
Calpain can also digest calpastatin and thus liberate inhibitory units
that are still active [28]. These fragments may be of great importance in
cells with altered calcium homeostasis as they promote ampliﬁcation of
the cells' inhibitory capacity [12,20].
Finally, calpastatin can be extensively degraded by calpain. Under
these conditions the cell is deprived of the capability to inhibit calpain
[28].
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studied at the structural level using a highly conserved recombinant
region of the inhibitory units found in full-length natural calpastatin
[29–31]. The inhibitory domain of calpastatin has thus been demon-
strated to bind both to the catalytic cleft and, to other sites in the EF-
hand regions of calpain domains IV and VI, if with lower afﬁnity and
only in the presence of Ca2+ [29–33]. Speciﬁcally, three conserved
sub-regions of the inhibitory domain (named A, B, and C [29]) are able
to interact with calpain through different binding sites. However,
whether these calpain sites can be occupied bymore than onemolecule
of calpastatin remains to be established [34].
Although the structural basis of calpain inhibition has been clariﬁed,
further study is still required because natural calpastatins contain not
only four inhibitory units, but also the L- and/or XL-domains, which
lack inhibitory activity [3,35].
The L-domain has been found to be involved in the calpain–
calpastatin interaction in the absence of Ca2+, which indicates that
this interaction does not require opening of the calpain catalytic cleft
[25].
As for full-length calpastatin, whether each inhibitory domain can
associate separately with a calpain molecule to form complexes having
different calpain:calpastatin stoichiometries has yet to be determined
[34]. Furthermore, as it has been demonstrated that, in the presence of
calcium, calpain can loosely aggregate [36], the number of calpastatin
molecules associated with these structures may be greater than one.
The fact that calpastatin forms having one or four inhibitory domains
display approximately the same inhibitory efﬁciency [37] points to a
1:1 stoichiometry.
Here we provide novel insights into the calpain–calpastatin com-
plex, based both on functional interactions and on competitive experi-
ments carried out to evaluate the role of the XL–L domains in the
kinetics of the enzyme–inhibitor complex formation. We found that
the calpastatin forms containing the XL–L- and L-domains lose inhibito-
ry efﬁciency at concentrations thatwould be expected to promote com-
plete calpain inhibition. We also established that interaction between
the inhibitory domain of calpastatin and the open substrate cleft of
calpain can occur either directly, or via the L-domain. The L-domain
seems to play a key role in directing proper positioning of the ﬁrst
inhibitory domain in the active site of calpain at high concentrations,
however, the calpastatin forms containing the XL–L domains are able
to interact, through the inhibitory domain, with an additional calpain
site. When this association occurs, correct binding of other calpastatin
molecules to the substrate cleft is prevented. Because this type of
interaction takes place in the presence of Ca2+ and does not promote
calpain inhibition, the still-active calpain molecules are able to degrade
calpastatin, thus producing free inhibitory units.2. Materials and methods
2.1. Materials
Leupeptin, aprotinin, 4-(2-amino-ethyl)benzensulfonyl ﬂuoride
(AEBSF), and ﬂuorescamine were purchased from Sigma Chem. Co.2.2. Puriﬁcation of the ubiquitous calpain forms
Human erythrocyte calpain was puriﬁed to homogeneity as
described in [38] and μ-calpain and m-calpain were puriﬁed from
rat skeletal muscle following the procedure described in [39,40].
The three puriﬁed proteases showed similar speciﬁc activities:
erythrocyte calpain 2100 units/mg, μ-calpain 2000 units/mg, m-calpain
1920 units/mg. One unit of calpain activity is deﬁned as the amount
required to cause the release of 1 μmol/h of free α-amino groups under
the speciﬁed conditions.2.3. Assay of calpain and calpastatin activity
Calpain activity was assayed using human acid-denaturated globin
as substrate, in the absence or in the presence of increasing amounts
of puriﬁed recombinant calpastatins, by measuring the amount of free
amino groups liberated following ﬂuorescamine-based quantitative
determination [40].
2.4. Preparation of recombinant calpastatins
RNCAST300, RNCAST600, and RNCAST110 (calpastatin L-domain
GenBank Y13590) proteins were prepared as described in [25,41]. The
protein constructs corresponding to the region of calpastatins cast468,
cast48, cast46, cast8, cast4, and castZERO (GenBank DQ186624–
DQ186629) containing the XL/L domains and only the ﬁrst inhibitory
unit (from exon 1xa to exon 12) were produced as described in [42].
To obtain recombinant full-length calpastatins (Type I (GenBank
AB026997), Type II (GenBank NM_009817.3), and Type III (GenBank
AK029293)), approximately 5 μg total RNA extracted from mouse
brain was reverse transcribed to cDNA with a random hexamer primer
(ThermoScript RT-PCR system Invitrogen). To obtain the three forms of
calpastatin by PCR, the cDNA was ampliﬁed in the presence of the spe-
ciﬁc forward primers: Type I: Sn EcoRI 5′-AAGAATTCAAAATGTCCCAG
CCCGG, Type II: Sn EcoRI 5′-AAGAATTCATGGCATTCGCAAGTTGGTG,
Type III: Sn EcoRI 5′-AAGAATTCATGAGTACCACAGAGACTAAGGCAATT
and the same reverse primer: Asn SalI 5′-AAAGTCGACGCTGAATTTCT
ATT-CAGATACCCA. PCR conditions were: a denaturation step for
1 min at 98 °C; then 95 °C for 30 s, 57 °C for 30 s, and 72 °C for 2 min
for 35 cycles. A 5-min extension step at 72 °C was performed after the
last cycle of PCR. Calpastatin amplicons were digested with EcoRI and
SalI and ligated into pGEX-6P1 GST Expression Vector (GE Healthcare).
GST–fusion constructs were transformed into Library efﬁciency DH5α
chemically competent Escherichia coli (Invitrogen) according to the
manufacturer's instructions. Recombinant protein expression was
induced by 4 h of incubation at 37 °C in the presence of 1 mM
isopropyl-D-thiogalactopyranoside (IPTG, Sigma). The resulting
GST–calpastatin constructs were puriﬁed by GST–agarose (Sigma) and
on-column digestion with PreScission protease (GE Healthcare).
2.5. Preparation of recombinant small subunit of calpain (30 kD)
For the preparation of recombinant human calpain small subunit (30
kD) (GenBank NM_001749.2) cDNA template was generated using 5 μg
of human lymphocyte total RNA. The transcript for the calpain 30 kD
subunit was obtained by PCR using the following primers: Sn BamH1
5′-TGGGATCCATGTTCCTGGTTAACTCGTTCTTGAAG, Asn XhoI 5′-AAAC
TCGAGGCTCCAGTTCAGGAATACATAGTCAGC. PCR conditions were: a
denaturation step for 1 min at 98 °C; then 95 °C for 30 s, 60 °C for 30
s and 72 °C for 1 min for 35 cycles. A 5-min extension step at 72 °C
was performed after the last cycle of PCR. After digestion by BamH1
and XhoI, the PCR product was cloned into pGEX-6P1 and a
recombinant small subunit of calpain was produced. To obtain the
puriﬁed protein the same protocol described above for the puriﬁcation
of recombinant full-length calpastatin was used.
Before cloning, the coding sequence of the clones containing the dif-
ferent calpastatin constructs and calpain small subunit, was conﬁrmed
by sequencing with a CEQ 2000XL DNA analysis system (Beckman
Coulter).
2.6. Determination of calpain and calpastatin concentrations
To prevent data errors in the calculation of IC50, the concentration of
each of the recombinant calpastatin species and of the native calpain
formswas established precisely. SDS-PAGE and Coomassie Blue staining
were performed to check for the presence of contaminating proteins
during the puriﬁcation steps. Finally, the concentration of each puriﬁed
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bovine serum albuminwas used as standard protein. The amount of the
amino groups liberated following alkaline hydrolysis was calculated by
ﬂuorescamine-based quantitative determination.
2.7. Immunoprecipitation
Immunoprecipitation was carried out by incubating RNCAST600
(0.5 μg) with increasing amounts of RNCAST110 (molar ratio
RNCAST600/RNCAST110, 1/1, 1/2, 1/4) in the presence of puriﬁed
human erythrocyte calpain (1 μg). The proteins were diluted in
50 mM sodium borate buffer pH 7.5, containing 1 mM EDTA (IP buffer)
and incubated with anti-calpain mAb 56.3 (0.5 μg) [44] for 2 h at room
temperature (50 μl, ﬁnal volume). Protein G–Sepharose (30 μl) diluted
1:1 in IP buffer was then added to the samples, and the mixtures were
rotated end-over-end for 2 h at 4 °C. Sepharose beads were collected
and washed three times with IP buffer (0.1 ml each wash). The beads
were then suspended in SDS-PAGE loading buffer (50 μl) and heated
for 5 min at 100 °C. The beads were discarded by centrifugation, and
the clear solutions were submitted to 15% SDS-PAGE followed by
Western blotting. The immunoprecipitated calpastatin species
were immunodetected with anti-calpastatin mAb 35.23 [37].
2.8. Curve ﬁtting and quantitative analysis of the two-site interactionmodel
for the calpain–calpastatin complex
Curve ﬁtting was performed using the nonlinear regression facility
(curve ﬁt) of GraphPad Prism version 4.0 (GraphPad Software Inc., SanFig. 1. Kinetics of calpain inhibition by RNCAST600 and RNCAST300. (A) Puriﬁed human eryt
amounts of recombinant RNCAST600 or RNCAST300. Calpain activity was measured as describe
between the activity of calpain in the absence of inhibitorminus the residual activity measured
of inhibitor (denominator) (see also the Materials and methods section). The data reported a
multiple recombinant calpastatin forms used in this paper. The numbers inside the rectanglesDiego, CA, USA). Multiple data sets generated several fractional inhibi-
tion versus calpastatin concentration curves. The data were collected
by measuring the activity of a ﬁxed amount of calpain (2 nM) in the
presence of different concentrations of calpastatin. Fractional inhibition
(indicated in the Y axis of Fig. 1–4) was calculated by measuring the
difference between the activity of calpain in the absence of inhibitor
minus the residual activity of the enzyme in the presence of calpastatin
(numerator), divided by the activity of calpain in the absence of inhibi-
tor (denominator). Thereby, when the ratio is 1, calpain residual activity
is zero. Calpain activitywasmeasured as the amount of\NH2 groups re-
leased from the digested globin substrate. The calpastatin concentration
required to promote 50% inhibition of calpain activity (fractional
inhibition = 0.5) is deﬁned as IC50.
2.9. Detection of calpastatin Type I, Type II and Type III protein levels in
skeletal muscle of control and FALS mice
Frozen skeletal muscle samples from control and transgenic mice
(100 days old) were kindly provided by Prof. G. Bonanno (Department
of Pharmacology, University of Genova, Italy). Aliquots (1 mg tis-
sue) were rapidly minced and resuspended in 3 volumes (w/v) of
chilled 50 mM sodium borate buffer, pH 7.5, containing 0.5 mM 2-
mercaptoethanol, 1 mM EDTA, 0.1 mg/ml leupeptin, 10 μg/ml aprotinin,
and 2 mM AEBSF. Minced tissue was homogenized 4 times for 15 s
with a Waring blender and lysed by sonication (4 bursts for 15 s with a
30 s cooling period between bursts). The particulate material was
discarded by centrifugation at 50,000 ×g for 10min at 4 °C. The superna-
tant was heated for 3 min at 100 °C and centrifuged at 50,000 ×g forhrocyte calpain (2 nM) was incubated for 10 min at 30 °C in the presence of increasing
d in theMaterials andmethods section. Fractional inhibition is calculated as the difference
in the presence of calpastatin (numerator), divided by the activity of calpain in the absence
re the arithmetic mean ± SD of ﬁve different assays. (B) Schematic representation of the
indicate the exons included in each domain.
Fig. 2. Evaluation of inhibitory efﬁciency (second phase) of RNCAST600 and RNCAST300.
To obtain the kinetics of the second phase curve (loss of inhibition), a representative
inhibition curve of RNCAST600 (A) and RNCAST300 (B), both reported in Fig. 1, has
been elaborated by calculating the difference between the inhibition values of the
theoretical curve minus the mean of the actual values obtained with both calpastatins. Fig. 3. Effect of RNCAST110 (L-domain) on calpain inhibition by RNCAST600 and
RNCAST300, and on the association of RNCAST600 with calpain. (A) Puriﬁed erythrocyte
calpain (2 nM) was incubated with increasing amounts of RNCAST600 in the absence or
in the presence of puriﬁed L-domain (2 nM) (+RNCAST110). Calpain activity was mea-
sured as described in the Materials and methods section. (B) Puriﬁed erythrocyte calpain
(2 nM) was incubated with RNCAST600 (3 nM) or RNCAST300 (3 nM) in the presence of
increasing amounts of puriﬁed L-domain (RNCAST110). Fractional inhibitionwas calculat-
ed as indicated in Fig. 1. The data reported in each curve are the arithmetic mean ± SD of
six different assays. (C) RNCAST600 (0.5 μg) or RNCAST110 (0.25 μg) was incubated with
puriﬁed human erythrocyte calpain (1 μg) (lanes 1 and 2). RNCAST600 (0.5 μg) was also
incubated with the indicated amounts of RNCAST110 in the presence of puriﬁed human
erythrocyte calpain (1 μg). The proteins were immunoprecipitated with anti-calpain
mAb 56.3 and the immunoprecipitated material was submitted to Western blotting.
Calpastatins were immunodetected with anti-calpastatin mAb 35.23.
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ted to 9% SDS-PAGE [45] and Western blotting [46]. The different forms
of calpastatin were detected with monoclonal antibody 35.23 [37], and
anti-calpastatin Domain IV mAb (Calbiochem). To distinguish between
calpastatin Type I and Type II two polyclonal antiserawere kindly provid-
ed by Prof. T. Parr (University of Nottingham, UK). The ﬁrst one detects
exon 1xa of calpastatin Type I, and the other exon 1xb of calpastatin
Type II [47].
The immune-reactive material was developed with an ECL detec-
tion system (GE Healthcare), detected with a Bio-Rad Chemi Doc XRS
apparatus, and quantiﬁed using the Quantity One 4.6.1 software
(Bio-Rad).2.10. Digestion of puriﬁed calpastatin Type III by calpain
Puriﬁed human erythrocyte calpain (4 pmol) was incubated at
25 °C in 0.04 ml of 50 mM sodium borate buffer, pH 7.5, containing
0.1 mM CaCl2 for 10 min in the presence of increasing amounts of re-
combinant calpastatin Type III in calpastatin to calpain molar ratios
ranging from 0.25 to 10. Reactions were stopped by addition of a
6× Laemmli loading solution, heated, and submitted to SDS-PAGE
(12%) and Western blotting. Calpastatin digestion was detected
with anti-calpastatin Domain IV mAb (Calbiochem). The amount of
15 kD species was detected and quantiﬁed as described above with the
Bio-Rad Chemi Doc XRS apparatus, and quantiﬁed using the Quantity
One 4.6.1 software (Bio-Rad).3. Results
3.1. Kinetics of calpain inhibition by RNCAST600 and RNCAST300
As the calpain–calpastatin association has been studied at the struc-
tural level using a single inhibitory domain [29–33], much remains to be
elucidated. In order to obtain data that can be more speciﬁcally related
to physiological conditions, we studied the inhibition kinetics of calpain
promoted bymultiple calpastatin forms that contain not only the inhib-
itory domain but also the N-terminal region, namely the XL–L and L-
domains.
We began by analyzing the inhibitory pattern of RNCAST600 [25],
which includes the ﬁrst inhibitory unit and the N-terminal L-domain.
As shown in Fig. 1A, the kinetics of calpain inhibition was characterized
by biphasic behavior. Speciﬁcally, at low RNCAST600 concentrations the
kinetics ﬁt with the curve of a competitive inhibitor having the same Ki
(evaluated as the inhibitor concentration promoting 50% inhibition,
IC50). At higher concentrations of RNCAST600, the degree of inhibition,
Fig. 4. Effect of calpain small subunit (30 kD) on calpain inhibition by RNCAST600. Puriﬁed
erythrocyte calpain (2 nM) was incubated with increasing amounts of RNCAST600 in the
absence or in the presence of recombinant calpain regulatory subunit (5 nM) (+R, dotted
curves). Fractional inhibition was calculated as indicated in the legend to Fig. 1. The loss of
inhibition curve was determined as described in the legend to Fig. 2. The data shown are
the arithmetic mean ± SD of six different experiments.
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and the second part of the curve diverged from the theoretical
one (Fig. 1A, dotted line). Even in the presence of a large excess of
RNCAST600, calpain retained 30–35% activity. Conversely, RNCAST300,
which contains the same inhibitory domain as RNCAST600, but lacks
the L-domain (see Fig. 1B for the structure of the various calpastatin
forms used in this paper), showed the classical kinetics, which is super-
imposable to the theoretical curve and corresponds to the formation
of an enzyme/competitive inhibitor complex (Fig. 1A), even at high
concentrations. Thus, this calpastatin form inhibits calpain almost
completely, as is the case with synthetic inhibitors such as leupeptin
[48].
Taken together these data suggest that the L-domain present in the
calpastatinmolecule affects its inhibitory efﬁciency bymodifying the as-
sociation of this calpastatin form with the catalytic cleft of calpain. The
unusual kinetics shown by RNCAST600 may be interpreted on the
basis of previous ﬁndings, which indicated that the inhibitory domain
of calpastatin can associate with calpain at multiple sites located both
at the catalytic and at the EF-hand domains [29–32].
As RNCAST600 differs from RNCAST300 exclusively for the presence
of the L-domain, it is reasonable to hypothesize that the biphasic kinet-
ics results from a direct interaction between the L-domain and calpain.
In this respectwe previously reported that the L-domain associateswith
a speciﬁc site on the calpain catalytic domain and that this association
occurs independently of the presence of Ca2+ [25]. This observation im-
plies that calpastatin can bind the inactive form of calpain. Therefore,
the inhibition kinetics of RNCAST600 may be due to the interaction be-
tween calpastatin and two distinct binding sites on calpain. The ﬁrst
interaction determines the inhibition of proteolytic activity and occurs
at the catalytic cleft, whereas the second, which promotes the decrease
of inhibitory efﬁciency, possibly involves the penta EF-hands.
To distinguish between these binding properties, we separated the
kinetics of calpain inhibition by RNCAST600 reported in Fig. 1 in two dif-
ferent curves (Fig. 2A): the ﬁrst curve shows the ﬁrst inhibitory phase,
while the other describes the second phase and is characterized by the
decrease of inhibitory efﬁciency. We calculated the loss of inhibitory
efﬁciency by evaluating the difference between the theoretical and the
actual RNCAST600 curve shown in Fig. 1. On the basis of this extrapola-
tion, it clearly appears that the inhibitory effect of RNCAST600 was
signiﬁcantly reduced at calpastatin concentrations greater than those
promoting about 50% inhibition andwas poorly increased at concentra-
tionsmore than ﬁve-fold higher. Indeed, after this initial phase atwhich
inhibition was the only detectable effect, the second phase took place
and calpain inhibition reached a plateau at concentrations ofRNCAST600 higher than 2 nM (Fig. 2A). The IC50 for the ﬁrst inhibitory
phase was approximately 1 nM. Much more calpastatin was required
to detect the loss of inhibitory efﬁciency observed during the second
phase, and maximal decrease of efﬁciency occurred at roughly 4–6 nM.
As expected, in the presence of RNCAST300, which is capable of pro-
moting full calpain inhibition, the second phase was almost undetect-
able (Fig. 2B). These different kinetic properties may be attributed to
the presence of the L-domain in RNCAST600. Alternatively, as suggested
by structural studies, they may be explained, by the existence of
multiple calpastatin binding sites on calpain [29–34]. Those structural
studies, however, did not include the L domain in the calpastatin con-
structs that they used, and therefore did not take its role into account.
Overall, the presence of more than one binding site on RNCAST600
suggests that the L-domain may promote the formation of an alterna-
tive calpain/calpastatin complex in which the calpain retains catalytic
activity.
3.2. Effect of the L-domain on calpain inhibition by RNCAST600 and
RNCAST300
In order to characterize the role of the L-domain within the biphasic
interaction between calpastatin and calpain, we tested the effect of the
isolated L-domain (RNCAST110) on calpain inhibition by RNCAST600.
As shown in Fig. 3A, the addition of 2 nM RNCAST110 to increasing
concentrations of RNCAST600 decreased calpain inhibition by approxi-
mately 50%, and the biphasic kinetics was still observed. When a ﬁxed
concentration of RNCAST600 was incubated with increasing amounts
of RNCAST110, calpain inhibition was progressively reduced (Fig. 3B).
Conversely, the presence of RNCAST110 had no effect on the RNCAST300
inhibition pattern (Fig. 3B). These kinetic data suggest that RNCAST110
and the L-domain present in RNCAST600 compete for a calpain binding
site which is distinct from the catalytic cleft.
With the aim of further exploring thismolecular interaction, we also
carried out immunoprecipitation experiments. As shown in Fig. 3C, both
RNCAST110 and RNCAST600 can be separately immunoprecipitated
with calpain. However, when we added increasing amounts of
RNCAST110 to a ﬁxed concentration of RNCAST600, the RNCAST600
bound to calpain was reduced proportionally to the amount of
RNCAST110 used. Since RNCAST110 has no effect on RNCAST300 inhib-
itory efﬁciency, we postulate that the two binding sites, although both
localized in calpain domain II, are functionally independent.
As observed with RNCAST600, all the calpastatin forms containing
the L-domain and at least one inhibitory unit (see also Table 2) showed
decreased calpain inhibition in the presence of RNCAST110 (data not
shown).
3.3. Effect of different exon compositions of the XL–L- and L-domains on the
inhibitory efﬁciency of different calpastatin forms
We sought further support for our multiple binding site hypothesis
by attempting to establish whether calpastatin forms that differ in
their exon composition display calpain inhibitory kinetics similar to
that of RNCAST600.
We tested the inhibitory efﬁciency of eleven recombinant calpastatin
forms in the presence of human erythrocyte calpain. IC50 values were
calculated by determining the amount of calpastatin required to pro-
mote 50% inhibition of calpain activity, and the decrease in inhibitory
efﬁciency detectable at high calpastatin concentrations during the
second phase, was measured as reported in Fig. 2A. We separately
analyzed these two parameters according to the exons composing
the XL–L domains and the multiple inhibitory units present in full-
length calpastatins. The data reported in Table 1 show that IC50 was
not directly related to the presence/absence of a single exon in the
XL–L domains. Selective exon composition, however, seemed to re-
ﬂect higher or lower afﬁnity for the catalytic cleft. The presence of ei-
ther exons 1xa, or 1xb did not signiﬁcantly affect IC50 values, nor the
Table 1
Effect of calpastatin domain composition on the biphasic inhibition of erythrocyte calpain.
Calpastatin
form
XL–L exon
composition
Inhibitory
domains
IC50
(nM)
Loss of inhibitory
efﬁciency (nM)
RNCAST300 None 1 1.0 ± 0.2 nd
RNCAST600 2, 4, 5, 6, 7, 8 1 1.3 ± 0.2 5 ± 1
Cast468 1xa, 1y, 2, 4, 5, 6, 7, 8 1 3.4 ± 0.2 5 ± 1
Cast46 1xa, 1y, 2, 4, 5, 6, 7 1 0.7 ± 0.1 9 ± 1
Cast48 1xa, 1y, 2, 4, 5, 7, 8 1 1.1 ± 0.2 10 ± 1
Cast8 1xa, 1y, 2, 5, 7, 8 1 3.1 ± 0.2 4 ± 1
Cast4 1xa, 1y, 2, 4, 5, 7 1 0.4 ± 0.1 13 ± 1
castZERO 1xa, 1y, 2, 5, 7 1 0.8 ± 0.1 10 ± 1
Type I 1xa, 1y, 1z, 2, 4, 5, 6, 7, 8 4 1.2 ± 0.3 7 ± 1
Type II 1xb, 1y, 1z, 2, 4, 5, 6, 7, 8 4 1.6 ± 0.3 7 ± 1
Type III 2, 4, 5, 6, 7, 8 4 1.3 ± 0.3 7 ± 1
Recombinant calpastatins were produced in E. coli and puriﬁed to homogeneity as de-
scribed in the Materials and methods section. Human erythrocyte calpain (2 nM) was in-
cubated in the presence of increasing amounts of each calpastatin form and both the
inhibition and loss of inhibition curves were separately generated as described in Fig. 2.
The values indicating the loss of inhibitory efﬁciency correspond to the concentration of
calpastatin required for the beginning of the second non inhibiting phase. Each value is
the arithmetic mean ± SD of four independent calpain assays.
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tain 4 repetitive domains showed IC50 values that were similar to the
forms having a single inhibitory unit. Thus, the non-inhibitory do-
main seems to play a role in positioning the ﬁrst inhibitory unit in
the proximity of the calpain active site cleft, regardless of the fact
that the catalytic pocket is in the closed or open conformation.
Both calpain sites may be occupied by the same calpastatin molecule
and the ﬁrst inhibitory domain may be inserted in the catalytic cleft.
As the additional inhibitory units present in full-length calpastatins
are ineffective, their role remains elusive.
We then found that the second phase of calpain inhibition (see
Table 1), which is characterized by lower inhibitory efﬁciency, occurred
in all the calpastatins containing the XL–L- or the L-domain. As men-
tioned above, RNCAST300, which is constituted of a single inhibitory
unit, lacked the second phase. Speciﬁcally, RNCAST600 and cast 468,
both of which contain the same L-domain and a single inhibitory unit,
differ only by the presence of the XL-domain in cast468. As the second
inhibition phase occurred at similar concentrations, we hypothesize
that the XL-domain is not involved in the decrease in inhibitory efﬁcien-
cy and that the presence of exon 1xa instead of exon 1xb in the XL-
domain (compare calpastatin Type I with Type II), has no impact on
the decrease in efﬁciency observed during the second phase.
Regarding the L domain (exons 2–8), we previously established in
rat brain that full-length calpastatin Type I undergoes alternative splic-
ing at exons 4, 6, and 8 [42]. We produced these splicing forms as re-
combinant proteins containing only the ﬁrst inhibitory unit. Table 1
shows that in cast4 (the alternative splice variant containing only
exon 4) unlike in cast8 (containing only exon 8) the decrease in inhibi-
tory efﬁciency occurs at a much higher calpastatin concentration.
Cast48 (which contains both exon 4 and exon 8), showed a loss in inhib-
itory efﬁciency that seems to reﬂect the functional contribution of each
exon alone. The concomitant presence of exon 6 (cast468) seems to be
synergistically related to the presence of exon 8. Indeed, cast468
showed very high afﬁnity for the second calpain site, which does not
promote calpain inhibition, while in cast46 the loss of inhibitory efﬁ-
ciency was similar to that of cast48.
We conclude that the presence of exon 4 seems to improve the in-
hibitory efﬁciency observed when either exon 8 or exon 6 is expressed.
Unexpectedly, the second phase of the calpastatin splicing form lacking
exons 4, 6, and 8 (castZERO) in the L-domain, was similar to that of cast
46 and cast 48. This ﬁnding suggests that these exons may be involved
both in the occurrence of the second phase and in other regulatory
functions mediated by post-translational modiﬁcations [23,27].3.4. Effect of calpain small subunit (30 kD) on calpain inhibition by
RNCAST600
With the aim of gaining further insights into the second phase of
RNCAST600 inhibition, we also explored the possible involvement of
calpain EF-hand regions in the decrease in inhibitory efﬁciency ob-
served at high calpastatin concentrations. Calpain is known to bind
the isolated calpastatin inhibitory unit [29–34] to both the large and
the small subunits in a Ca2+-dependentmanner, as each of the subunits
contains ﬁve EF-hands [1–3]. Therefore we expressed recombinant
30 kD calpain small subunit and studied its effect on the formation of
the calpain-RNCAST600 complex.
As shown in Fig. 4, calpain inhibition by RNCAST600 is increased in
the presence of the isolated 30 kD subunit, whereas the loss of inhibito-
ry efﬁciency (second phase) is signiﬁcantly delayed and reduced. Based
on these observations we infer that the EF-hand regions are directly in-
volved in the formation of a calpain–calpastatin complex, which under
these experimental conditions leaves the calpain active site accessible
to the inhibitor. Thus the “loss of inhibitory efﬁciency” observed only
at high calpastatin concentrations may be determined by the fact that
the inhibitor binds to the small subunit of a given calpain molecule be-
cause the afﬁnity of calpastatin for the 30 kD subunit is lower than its af-
ﬁnity for the active site. The result of this interaction is that no more
calpastatin can reach the catalytic cleft.
Under our experimental conditions the excess of free 30 kD subunits
determines the competitive removal of calpastatin from the small sub-
unit of the native calpain. Consequently, as more calpastatin molecules
reach the catalytic cleft calpain inhibition is increased.
In conclusion, binding of calpastatin to one calpain site excludes in-
teraction of another inhibitormoleculewith the other site. This explains
the persistency of residual calpain activity even in the presence of an
excess of calpastatin.
As shown in Table 2 the effect of the 30 kD subunit was observed in
all the calpastatin forms containing the L-domain. Exceptions are
RNCAST300, which lacks the L-domain, and calpastatin Type III, which
is deprived of the XL-domain and contains four inhibitory units. This
observation further conﬁrms the role of the L-domain in the formation
of a functional enzyme–inhibitor complex.
3.5. Different speciﬁcity and inhibitory efﬁciency of the various calpastatin
forms assayed in the presence of ubiquitous members of the calpain family
We incubated recombinant full-length calpastatins [35], in the pres-
ence of μ- andm-calpains puriﬁed from rat skeletal muscle. As shown in
Table 3, Type I efﬁciently inhibited both calpain isozymeswhereas Type
II wasmore effective on μ-calpain thanm-calpain. Type III, which differs
fromTypes I and II as it lacks the XL-domain, displayed similar efﬁciency
on both calpains. For purpose of comparison, Table 3 also shows the ef-
fect of these calpastatins on erythrocyte calpain, which belongs to the μ-
calpain family. These ﬁndings may indicate that the lower inhibitory
efﬁciency observed for Type II calpastatin on m-calpain results from a
different type of interaction between Type II and the catalytic subunit
of m-calpain, as calpains share the same regulatory subunit [3].
3.6. Expression of the different calpastatin forms in skeletal muscle of SOD1
transgenic mice
We explored whether different calpastatin forms undergo differen-
tial regulation of their expression level depending on the activation/
activity of the Ca2+-dependent proteolytic system. To this purpose we
measured the protein levels of calpastatin Types I, II, and III in skeletal
muscle from SOD1 transgenicmice. These animals are generally utilized
as a model for studying Familial Amyotrophic Lateral Sclerosis (FALS)
and display altered calcium homeostasis [12].
As reported in Table 4, we observed that the amounts of Type I and
Type II were increased in FALS mice vs. control animals, whereas the
Table 2
Changes in the inhibitory efﬁciency of different calpastatin species incubated with erythrocyte calpain, in the presence of isolated L-domain or 30 kD regulatory subunit.
Calpastatin form Domain composition Inhibitory effect of the L-domain (RNCAST110) Inhibitory effect of the regulatory subunit (30 kD)
RNCAST300 1 nd nd
RNCAST600 L-1 ↓ ↑
Type I XL–L–1–2–3–4 ↓ ↑
Type II XL–L-1–2–3–4 ↓ ↑
Type III L-1–2–3–4 ↓ ↓
Human erythrocyte calpain (2 nM) was incubated in the presence of increasing amounts of each calpastatin form in the absence or in the presence of RNCAST110 (2 nM) or calpain reg-
ulatory subunit (30 kD) (5 nM). To establish if the addition of exogenous free L-domain (RNCAST110) or 30 kD regulatory subunit promotes an increase (↑) or a decrease (↓) in calpain
inhibition by the indicated calpastatins, fractional inhibition versus calpastatin concentration curves have been generated. For each calpastatin form the curves plotted in the absence and
in the presence of the free domains were compared (see Fig. 3A and 4). Experiments were carried out as reported in the legend to Fig. 3A and 4.
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modiﬁed.
Alongwith these three forms, FALS animal skeletalmuscle contains a
fourth calpastatin species with a mass of about 15 kD. This form, which
is not produced by a speciﬁc mRNA, derives from calpain-mediated di-
gestion of full-length calpastatins. This process causes the liberation of
free inhibitory domains that retain inhibitory activity [12,20,28,49].
As shown in Fig. 5, we detected accumulation of 15 kD fragments
in vitro when a large excess of full-length calpastatin was exposed to
calpain proteolysis. Therefore, under this condition, following associa-
tionwith the second site, native calpastatin, prevented complete inhibi-
tion of calpain.
Taken together, these data provide new insights into the role of the
15 kD form. This form shows high inhibitory efﬁciency, and is able to
control calpain activation. Our observations indicate that the second
site is involved in the recognition of calpastatin as a substrate.
4. Discussion
Interaction of calpain with calpastatin is considered to be the most
important and speciﬁc regulatory mechanism of protease activity. A
detailed structural analysis of a complex formed between calpain and
one of the four calpastatin inhibitory domains has provided important
information on the binding sites involved [29–34].
It has been previously reported that in addition to calpain catalytic
cleft, an isolated calpastatin inhibitory domain can bind to multiple
lower afﬁnity sites that are localized in the EF-hand domains IV and VI
of calpain, thereby stabilizing the inhibitory complex [30,33,34].
To explore the role of the other domains in full-length calpastatins
we analyzed the interaction between calpain and different calpastatin
constructs that contain the XL–L or L- N-terminal domains and one or
four inhibitory units. We have established that the L-domain is respon-
sible for the decrease in inhibitory efﬁciency at high calpastatin concen-
trations. As a result, even in the presence of an excess of calpastatin,
calpain is never fully inhibited. Our observations indicate that the L-
domain recognizes a site at calpain domain II not coincident with the
catalytic cleft and which possibly delivers the downstream inhibitoryTable 3
Inhibitory efﬁciency (IC50, nM) of different calpastatin forms on ubiquitous calpains.
Calpastatin form μ-Calpain Erythrocyte calpain m-calpain
RNCAST300 0.9 ± 0.1 1.0 ± 0.2 1.9 ± 0.3
RNCAST600 1.0 ± 0.2 1.3 ± 0.2 1.4 ± 0.3
Type I 1.1 ± 0.2 1.2 ± 0.3 1.5 ± 0.2
Type II 1.3 ± 0.2 1.6 ± 0.3 3.5 ± 0.2
Type III 1.2 ± 0.1 1.3 ± 0.3 1.3 ± 0.2
Recombinant calpastatins were produced in E. coli and puriﬁed to homogeneity as de-
scribed in the Materials and methods section. Ubiquitous μ-calpain and m-calpain were
puriﬁed from rat skeletal muscle as described in the Materials and methods section and
in [3]. Both enzymes (2 nM) were separately incubated in the presence of increasing
amounts of each calpastatin form and residual calpain activity has beenmeasured. Inhibi-
tion curves have been generated to calculate IC50 and each value is reported as the arith-
meticmean ± SDof ﬁve different calpain assays. For comparison the IC50measured in the
presence of erythrocyte calpain and already indicated in Table 1 is also reported.unit to the substrate cleft. Furthermore, the calpastatin forms containing
the L-domain associate with additional sites at the EF-hand regions of
calpain, via their inhibitory domain, although with lower afﬁnity and
in the presence of Ca2+. These sites have been previously identiﬁed by
structural studies carried out with recombinant calpastatin constructs
lacking the L-domain [29–34].
Thus, the presence of the L-domain could increase the afﬁnity of the
downstream inhibitory unit for the active cleft andwhen this complex is
formed, calpain is inhibited. At higher calpastatin concentrations the as-
sociation of the inhibitor with calpain occurs at the other sites in the EF-
hands of the protease. We hypothesize that in the presence of Ca2+, the
interaction of the calpastatin forms containing the L-domainwith the EF
hands, could create a steric hindrance that hampers the binding of an-
other calpastatin molecule at the catalytic site. In these conditions
calpain retains activity and can digest substrates including another
calpastatin molecule. The data herewith reported, besides suggesting a
mechanism by which calpastatin can reduce its inhibitory efﬁciency,
also provide an explanation for the fact that full-length calpastatins
show an inhibitory efﬁciency similar to that of the forms having only
the ﬁrst inhibitory domain.
Yet we want to stress that our ﬁndings are not in disagreementwith
previous studies reporting that calpastatin can simultaneously bind four
calpain molecules, one for each inhibitory unit [34]. It should be noted
that the calpastatin construct used by Hanna et al. is just lacking the L-
domain which is essential in our experiments to detect the biphasic ki-
netics of calpain inhibition. Moreover, our data are based on functional
measurements of calpain inhibition rather than on the structural char-
acterization of the calpain/calpastatin interaction. In the model here
presented the association of calpastatin with calpain does not necessar-
ily lead to the inhibition of the protease.
Interestingly, the calpain molecules that are not inhibited by
calpastatin digest the inhibitor to free 15 kD inhibitory units. This pro-
cess can also be directed to calpastatin species that have lost the L-
domain but still contain more than one repetitive unit. The binding of
these calpastatins to the EF-hand structures promotes the association
with calpain active site, of other calpastatin molecules that are ﬁrst
digested to 15 kD inhibitory units, and then foreshortened to inactive
fragments [28].Table 4
Protein level of the different calpastatin forms in skeletal muscle of control and FALSmice.
Calpastatin level (arbitrary units)
Calpastatin form Control FALS
Type I 35 ± 8 65 ± 10
Type II 135 ± 16 276 ± 18
Type III 525 ± 48 405 ± 34
15 kD 10 ± 4 235 ± 20
Clear heated extracts were obtained from skeletal muscle of control and FALS mice as
described in the Materials and methods section. Aliquots (75 μg) were submitted to
SDS-PAGE and Western blotting. The different calpastatin forms were detected using the
speciﬁc antibodies (see the Materials and methods section). The amount of each
calpastatin reactive band was quantiﬁed as described in the Materials and methods sec-
tion, using Quantity One 4.6.1 software (Bio-Rad).
Fig. 5. Production of 15 kD species by calpain-mediated digestion in conditions of high
calpastatin concentrations. Puriﬁed human erythrocyte calpain (4 pmol) was incubated
in the presence of increasing amounts of recombinant Type III calpastatin (up to
40 pmol) at the indicated calpastatin/calpain molar ratios. The 15 kD calpastatin species
was detected by Western blotting and quantiﬁed by densitometric analysis using the
Chemi Doc XRS system (Bio-Rad) as described in the Materials and methods section and
in [12]. The values reported are the arithmetic mean ± SD of ﬁve different experiments.
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the inhibitor was nearly absent and the calpastatin fragments were al-
most undetectable [51]. Now we can hypothesize that the low levels
of calpastatin in red blood cells from hypertensive patients [50] and
the absence of inhibitor in genetically hypertensive rats [51] may be
due to non-conservative degradation of calpastatin. Hence, while the
presence of the L-domain could limit the digestion of calpastatin by fa-
voring the correct positioning of the inhibitory unit in calpain active site,
the absence of this domain induces calpastatin digestion at a higher rate
as observed in erythrocytes from hypertensive rats.
Instead, we detected high levels of free calpastatin inhibitory do-
mains in tissues actively synthesizing new calpastatin molecules and
in conditions of elevated and prolonged alterations in Ca2+ homeosta-
sis, such as in hypertension and amyotrophic lateral sclerosis [12,49].Fig. 6.Model for the formation of alternative complexes between calpain and L-domain-containi
I–IV) and the regulatory (domains V–VI) subunits are shown. The functional thiol group of the c
and one inhibitory unit (subdomains A, B, C are evidenced) is also shown.The maintenance of calpain activity also in the presence of high levels
of calpastatin could be important to overcome these dangerous condi-
tions because new calpastatin fragments, more efﬁcient than the inhib-
itor species originally expressed in the cells, are produced [12,20,49].
Thereby, the alternative binding of calpastatin to calpain, which is
determined by the presence of the L-domain, can be visualized as a
mechanism responsible for the transition of calpastatin from an inhibi-
tor to a calpain substrate. It may indicate that within physiological and
transient variations in [Ca2+]i, calpastatin can regulate calpain activity
by a classical enzyme–inhibitor interaction. Conversely, a large and per-
sistent increase in [Ca2+]i promotes fragmentation of the inhibitor to
overcome the severe cell conditions caused by abnormal calpain activa-
tion [12,20,49]. Indeed, these calpastatin fragments provide a very
efﬁcient inhibitory device that, at difference with native calpastatins,
cannot be antagonized by any other inhibitory or non-inhibitory
calpastatin species.
In conclusion, our ﬁndings demonstrate that the L-domain, which in
itself lacks inhibitory capacity, plays a key role in regulating the inhibi-
tory efﬁciency of calpastatin. The existence of this functional role is sup-
ported by our experimental results, which show that all the calpastatin
forms naturally expressed and containing the L-domain are character-
ized by a biphasic calpain inhibition curve. The observation that a mas-
sive accumulation of the 15 kD species in skeletal muscle of FALS
animals occurs alongwith Ca2+ increase and over-activation of calpain,
provides additional support to the model herewith proposed (Fig. 6).
(A) Binding of the L-domain to calpain domain II positions the ﬁrst
inhibitory unit in close and correct proximity to the calpain active site
cleft. In the presence of Ca2+ calpain is inhibited. An excess of free L-
domains induces a decrease in calpain inhibition because the exogenous
L-domains interfere with the correct association of calpastatin with the
catalytic cleft. (B) The L-domain containing-calpastatin associates with
the EF-hand structures both in domains IV and VI of calpain through
its inhibitory unit and in the presence of Ca2+. In this complex, the cat-
alytic site cannot be occupied by the inhibitory unit of a full-length
calpastatin and calpain is active. Exogenous 30 kD calpain subunitsng calpastatins. Calpain heterodimer (gray) is schematized andboth the catalytic (domains
atalytic cleft is also indicated. A calpastatinmolecule (white) containing the XL–L domains
2591R. De Tullio et al. / Biochimica et Biophysica Acta 1843 (2014) 2583–2591compete with the regulatory subunit of native calpain for binding to
calpastatin. As a result, the amount of the calpastatin interacting with
the EF-hands of calpain is reduced, and more inhibitor can correctly as-
sociate with the catalytic cleft, thus leading to increased calpain inhibi-
tion. (C) Since binding of calpastatin to the EF-hand sites leaves the
active site accessible, another molecule of inhibitor can be inserted in
the catalytic cleft and undergo limited proteolysis with the production
of free, still-active 15 kD calpastatin fragments. Under these conditions
calpain is not inhibited and calpastatin behaves as a substrate.
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